Viatris (VTRS) | Stock Overview & Key Data
Viatris Performance Comparison
Stock Range
Today's Range
Low: $9.94
High: $10.19
on October 2, 2025
52 Week Range
Low: $6.85
High: $13.55
on April 10, 2025
on November 25, 2024
All-Time High: $76.69 on April 20, 2015
Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights
Key Statistics
Market Cap
$11.8B
EPS
-2.96
P/E Ratio (TTM)
235.80
Forward P/E
3.60
P/B Ratio
0.72
PEG Ratio
-2.36
Div. Yield
6.19%
ROE
-19.77%
Beta
0.924
Debt to Equity
95.12
Financial Highlights
Profitability
Gross Margin
37.21%
Operating Margin
9.95%
Profit Margin
-24.57%
Returns and Earnings
Return on Assets (TTM)
2.30%
Return on Equity (TTM)
-19.77%
EBITDA
$2.5B
Net Income (TTM)
$-3.5B
Growth
Revenue (TTM)
Revenue Per Share (TTM)
$11.83
Quarterly Revenue Growth (YoY)
-5.70%
Quarterly Earnings Growth (YoY)
-5.65%
Dividend Information
Last 12-Month Dividend
$0.60
Current Dividend Yield
6.19%
3-Year Average Dividend Yield
1.17%
3-Year Average Annual Dividend
$0.52
3-Year Total Dividends
$1.56
Ex-Dividend Date
August 22, 2025
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Viatris VTRS | 11.77B Large-cap | 6.53% | -4.26% | 8.24% | 16.74% | -18.60% | -12.77% | 15.68% | -35.36% |
| Haleon Plc - ADR HLN | 41.72B Large-cap | 1.83% | -9.02% | -13.45% | -12.60% | -5.93% | -14.37% | 45.81% | 19.84% |
| United Therapeutics UTHR | 19.33B Large-cap | 4.24% | 9.54% | 50.21% | 42.01% | 23.10% | 24.59% | 114.46% | 326.34% |
| Intra-Cellular ITCI | 14.05B Large-cap | 0.14% | 0.45% | 56.54% | 82.52% | 56.54% | 92.68% | 104.13% | 700.67% |
| Neurocrine NBIX | 13.75B Large-cap | -2.95% | -3.65% | 5.67% | 26.25% | -0.81% | 19.95% | 26.32% | 30.95% |
| Zoetis ZTS | 63.73B | -1.63% | -7.29% | -7.89% | -11.87% | -11.75% | -26.34% | -3.23% | -12.26% |
Ownership & Short Interest
Insider Ownership
0.28%
Institutional Ownership
85.55%
Shares Short
42M
Short Ratio
4.73
Short % of Shares Outstanding
4.09%
Average 10-Day Volume
13M
Average 90-Day Volume
10M
Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is VTRS's 52-week high and low?
- In the last 52 weeks, Viatris reached a high of $13.55 (on November 25, 2024) and a low of $6.85 (on April 10, 2025).
- What is the market cap and P/E ratio for VTRS?
- Curious about Viatris's size and valuation? Its market capitalization stands at 11.77B. When it comes to valuation, the P/E ratio (trailing twelve months) is 235.80, and the forward P/E (looking ahead) is 3.60.
- Does VTRS pay dividends? If so, what's the yield?
- Yes, Viatris is a dividend-paying stock. Investors have recently enjoyed a trailing annual dividend yield of 6.19%, and the company has paid an average of $0.52 per share annually over the past 3 years.
- Who are Viatris's main competitors or similar companies to consider before investing?
When looking at Viatris, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Haleon Plc - ADR
HLN41.72B Healthcare Drug Manufacturers - Specialty & Generic -14.37% 45.81% United Therapeutics
UTHR19.33B Healthcare Drug Manufacturers - Specialty & Generic 24.59% 114.46% Intra-Cellular
ITCI14.05B Healthcare Drug Manufacturers - Specialty & Generic 92.68% 104.13% Neurocrine
NBIX13.75B Healthcare Drug Manufacturers - Specialty & Generic 19.95% 26.32% Zoetis
ZTS63.73B Healthcare Drug Manufacturers - Specialty & Generic -26.34% -3.23% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Viatris Inc.? (e.g., ROE, Debt/Equity)
- To get a sense of Viatris's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is -19.77%, the Debt to Equity ratio from the most recent quarter is 95.12, and its Gross Profit Margin stands at 37.21%.
- What is the recent revenue and earnings growth for VTRS?
- Looking at Viatris's growth, its revenue over the trailing twelve months (TTM) was $14B. Compared to the same quarter last year (YoY), quarterly revenue grew by -5.70%, and quarterly earnings saw a YoY growth of -5.65%.
- How much of VTRS stock is held by insiders and institutions?
- Wondering who owns Viatris stock? Company insiders (like executives and directors) hold about 0.28% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 85.55%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.